Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | BMC Cancer

Figure 4

From: Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines

Figure 4

Effect of panobinostat on DNMT and target gene expression in vivo . HepG2 xenograft specimens were analyzed for expression of (A) DNMTs after 1, 7 and 28 days of daily i.p. injections of 10 mg/kg panobinostat. Results were normalized to the GAPDH content of each sample and represent mean ± relative error of 5 to 10 independent samples per group and are expressed relative to expression levels of untreated control animals with the set value of 1.0 for each point in time. (B) Methylation status and total expression level of APC and RASSF1A were analyzed at day 7 and day 28 of panobinostat treatment. Results are normalized to levels of untreated controls. Methylation of RASSF1A was not detectable in untreated controls and in treated animals at day 7. * P < 0.05 vs. untreated controls.

Back to article page